Polaryx Therapeutics, Inc.

PLYX · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $0.2B
6
SEC Filings
$2.26
Close 2026-08-07

Business Summary

Polaryx Therapeutics is a clinical-stage biotechnology company developing novel disease-modifying therapies for rare, pediatric lysosomal storage diseases (LSDs). Its pipeline includes PLX-200 (gemfibrozil, oral small molecule), PLX-300 (cinnamic acid), PLX-100 (combination therapy), and PLX-400 (gene therapy). Lead candidate PLX-200 is advancing through a Phase 2 basket trial (SOTERIA) targeting CLN2, CLN3, Krabbe disease, and Sandhoff disease, with an FDA-cleared IND received in October 2025.

Latest Stock Quote

PLYX 2026-08-07 $2.26 O:$2.18 H:$2.3 L:$2.18 Vol:0.1M VWAP:$2.2604
origin leaf: null

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-242025-12-310001213900-26-033064EDGAR102K words

Quarterly Reports (10-Q)

No 10-Q filings indexed.

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-07-210001213900-26-080041EDGAR—
2026-07-170001213900-26-078912EDGAR—

6 total filings indexed. 3 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACIU — AC Immune SA ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA

Tags

rare-pediatric-lysosomal-storage-diseases-(lsds) neuronal-ceroid-lipofuscinoses-(ncls) krabbe-disease gm2-gangliosidoses-(tay-sachs-and-sandhoff-diseases) niemann-pick-disease-types-a-and-b orphan/rare-disease-therapeutics 505(b)(2)-regulatory-pathway ppar-dependent-upregulation-of-tfeb lysosomal-biogenesis-via-tfeb-activation pi3k-pathway-activation

Company Identity

CIK0002075320
TickerPLYX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedWY
Websitehttps://www.polaryx.com
Listed2026-02-02

Get More Data

This is a static snapshot. For live, structured JSON with cryptographic provenance chain:

MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: d96dfae934e61b70aee338c5ea3b4261c5dd0a1028d92012baed979ef5cc3018
parent: e5e4b7f4e395b3c4164edf8b089be7b8383d72d069b4ed0543c57da74d68d568
content hash: 4fd996316ed6080e1b24e0007201ada885ce37159be734b01ac50c3d5cc74005
signed: 2026-08-10T19:04:59.619Z
sources: 1 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf

Try it — paste this into your AI:

Look up PLYX using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?

Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.

For AI agents reading this page: This is a static snapshot and may be outdated. For live data on PLYX, use the Origin MCP server or REST API.
MCP install: claude mcp add origin --transport http https://origin.rootz.global/mcp
API: GET https://origin.rootz.global/api/company/PLYX (~200 tokens, structured JSON with cryptographic provenance)
Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill
Discovery: /.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.